BHBing Han

Bing Han

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bing Han has a total of 289 co-authors. Here are the top co-authors by number of shared publications:

  • Wei Du

    Division of Cardiology, Xuzhou Central Hospital, Xuzhou Clinical School of Xuzhou Medical University, Xuzhou Institute of Cardiovascular Disease, Xuzhou, China

    6 shared publications
  • Wenwu Zhu

    Xuzhou Clinical School of Xuzhou Medical University, Division of Cardiology

    6 shared publications
  • Hao Yang

    Division of Cardiology, Xuzhou Central Hospital, Xuzhou Clinical School of Xuzhou Medical University, Xuzhou Institute of Cardiovascular Disease, Xuzhou, China

    5 shared publications
  • Mu Qin

    Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    5 shared publications
  • Xu Liu

    Department of Cardiology, Shanghai Jiao Tong University School of Medicine, Shanghai Chest Hospital, China (K.L., M.Q., W.J., Y.Z., S.W., K.X., X.L., X.H.).

    5 shared publications
  • Kai Xu

    Department of Cardiology Shanghai Chest Hospital Shanghai Jiao Tong University Shanghai China

    4 shared publications

Latest Publications

  • Open Access

    Incidence of silent cerebral embolisms after radiofrequency ablation of atrial fibrillation using Thermocool SmartTouch Surround Flow catheter

    by Meng Wang, Wei Du, Hao Yang, Yalan Fei, Qingshan Dong, Xianjin Li, Shijie Li, Ruxing Wang, Bing Han

    Background and Aims: This study aimed to investigate the incidence of silent cerebral embolisms (SCEs) after catheter ablation of atrial fibrillation (AF) using the ThermoCool SmartTouch Surround Flow (STSF) catheter compared to the ThermoCool SmartTouch (ST) catheter. Methods: This study prospectively enrolled patients who underwent de novo AF ablation using either STSF or ST catheter from December 2022 to February 2024. Cerebral magnetic resonance imagings (MRI) were performed within 24 to 48 h after the procedure to detect the new-onset SCEs. The incidences of SCEs, along with the clinical and procedural data, were compared between the patients using STSF catheter and ST catheter. Risk factors associated with SCEs were analyzed by logistic regression. Results: In this study involving 163 patients, AF ablation was conducted using a STSF catheter in 50 patients (the STSF group) and a ST catheter in the remaining 113 patients (the ST group). No significant differences were observed in baseline clinical and demographic characteristics between the two groups. There were no apparent differences in the procedural data between the two groups. The incidence of SCEs was significantly lower in the STSF group compared to the ST group (16% vs. 33.6%, P = 0.021). Multivariate logistic regression analysis indicated that the left ventricular ejection fraction and the use of STSF catheter were independently associated with SCEs after AF ablation. Conclusion: Using STSF catheters instead of ST catheters may be associated with reduced incidence of SCE following AF ablation.

  • Transcatheter Aortic Valve Replacement in Pure Aortic Regurgitation: The Randomized SEASON-AR Clinical Trial

    by Xiao-Fei Gao, Yan Wang, Hong Jiang, Bo Li, Yi-Bing Shao, Jun Luo, Fa-Xin Ren, Fan Ouyang, Zhi-Kui Chen, Hai-Tao Yuan, et al.

    BACKGROUND: For patients with severe pure aortic regurgitation (AR) at high surgical risk, guideline-directed medical therapy (GDMT) is often the only available option. Transfemoral transcatheter aortic valve replacement (TAVR) is an established treatment for aortic stenosis and has also been evaluated in patients with pure AR. However, no adequately powered randomized trial has compared TAVR with GDMT alone in this population. METHODS: We conducted a prospective, investigator-initiated, multicenter, randomized, open-label trial in China. Patients with severe pure AR for whom surgery was considered difficult or unacceptable by the local heart team or who persistently declined surgery were randomly assigned at a 1:1 ratio to receive transfemoral TAVR with the VitaFlow system plus GDMT or GDMT alone. The primary end point was a composite of all-cause death, disabling stroke, or heart failure rehospitalization at 1 year. RESULTS: We assigned 210 patients with severe pure AR to the TAVR group (n=109) or GDMT group (n=101) at 18 centers. At 1-year follow-up, the Kaplan-Meier estimate of the primary end point was significantly lower in the TAVR group than in the GDMT group (8.3% vs 24.8%; hazard ration [HR], 0.31 [95% CI, 0.14–0.66]; P =0.001), driven primarily by a reduction in heart failure rehospitalization (3.7% vs 21.3%; HR, 0.16 [95% CI, 0.06–0.47]; P < 0.001). TAVR was associated with higher rates of major or life-threatening bleeding and new permanent pacemaker implantation, most of which occurred within 30 days after the procedure. CONCLUSIONS: Among patients with severe pure AR, TAVR plus GDMT significantly reduced the rate of all-cause death, disabling stroke, or heart failure rehospitalization at 1 year compared with GDMT alone despite higher 30-day rates of major or life-threatening bleeding and new permanent pacemaker implantation. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04864145

  • Open Access

    Mid‐Term Clinical Outcomes According to CTO Revascularization Status in Patients With NSTEMI and Multivessel Disease

    by Wei Liu, Yuling Li, Wei Qin, Jixian Gao, Bo Liu, Chongyou Rao, Bing Han

    Background: The clinical relevance of chronic total occlusion (CTO) revascularization in patients with non–ST‐segment elevation myocardial infarction (NSTEMI) and multivessel disease (MVD) remains uncertain. Methods: In this multicenter retrospective cohort study, 632 patients with NSTEMI, MVD, and CTO were included. Patients were categorized into a complete revascularization group involving successful CTO recanalization (CR‐CTO, n = 119) and an incomplete revascularization group without successful CTO recanalization (ICR‐CTO, n = 513). The primary endpoints were major adverse cardiovascular and cerebrovascular events (MACCE) and major adverse cardiovascular events (MACE). Results: During a mean follow‐up of 528 ± 201 days, the incidences of MACCE (11.8% vs. 28.5%) and MACE (7.6% vs. 24.2%) were significantly lower in the CR‐CTO group than in the ICR‐CTO group (both p < 0.001). In multivariable Cox regression analyses, CR‐CTO was independently associated with lower risks of MACCE (hazard ratio [HR], 0.35; 95% confidence interval [CI], 0.20–0.61) and MACE (HR, 0.26; 95% CI, 0.13–0.51). Among patients without successful CTO recanalization, additional revascularization of non‐CTO lesions was not associated with improved outcomes. Conclusions: In patients with NSTEMI, MVD, and CTO, complete revascularization involving successful CTO recanalization was associated with improved mid‐term clinical outcomes. In contrast, additional revascularization of non‐CTO lesions alone was not associated with a prognostic benefit when CTO lesions remained unrevascularized. These findings suggest that CTO revascularization status may warrant specific consideration when revascularization strategies are evaluated in this patient population.

  • Open Access

    Cryoballoon ablation versus antiarrhythmic drug therapy as initial treatment for persistent atrial fibrillation: the multicenter randomized CEPAF trial

    by Tianyou Ling, Yazhou Lin, Yangyang Bao, Lin Chen, Wei Xu, Baopeng Tang, Jing Xu, Jingquan Zhong, Wei Li, Zhongbao Ruan, et al.

    Background and Aims: Evidence supporting first-line cryoballoon ablation (CBA) in treatment-naive persistent atrial fibrillation (PersAF) is limited. Consequently, we compared CBA with guideline-directed antiarrhythmic drug (AAD) therapy in this advanced form of disease. Methods: This multicenter, prospective, randomized, open-label trial assigned 320 symptomatic, treatment-naive patients with PersAF (1:1) to CBA or AAD therapy. The primary endpoint was the first documented atrial tachyarrhythmia recurrence lasting at least 30 seconds during days 91-365. Secondary endpoints included recurrence during days 1-90 and 1-365, time-to-first recurrence, quality of life, and safety. Results: In the intention-to-treat population, recurrence during days 91-365 occurred in 30/160 (18.8%) patients assigned to CBA and 71/160 (44.4%) assigned to AAD therapy (absolute difference, -25.6 percentage points; 95% confidence interval, -35.4 to -15.8; P<0.001). Supportive time-to-event analysis favored CBA (hazard ratio for AAD vs. CBA, 2.29; 95% confidence interval, 1.48-3.56; log-rank P<0.001). In CBA vs AAD comparisons, overall recurrence during days 1-365 was 23.8% vs. 55.6%, and early recurrence was 11.2% vs. 28.1% (both P<0.001; respectively). Improvement in AFEQT score was greater with CBA (17.3 vs. 6.6 points; P<0.001); whereas SF-12 component scores did not differ significantly. Adverse events recorded on event forms were infrequent in both cohorts. Conclusion: In selected treatment-naive patients with PersAF, first-line CBA reduced atrial tachyarrhythmia recurrence and improved disease-specific quality of life compared with AAD therapy.

  • Open Access

    Activation of Endothelial TRPV4 Exacerbates Myocardial Ischemia-Reperfusion Injury via Vascular Integrity Impairment

    by Miaomiao Zhang, Yan Zou, Hongyun Ruan, Yingyu Chen, Zixuan Li, Yan Liu, Yimei Du, Bing Han


  • Analysis of Similarities and Differences between Biatrial Remodeling Through Electro-Anatomic Mapping in Patients with Atrial Fibrillation

    by Yue-Yue Feng, Bing Han

    This study aims to explore the association between LA and RA remodeling and their influences on ablation efficacy in AF patients. The study involved AF patients undergoing their first catheter ablation using CARTO 3 system. After isolating pulmonary veins, three-dimensional electro-anatomical mapping (3D-EAM) of LA and RA was conducted during sinus rhythm. Low voltage area (LVA) was defined as regions with bipolar voltage < 0.5 mv. If LVA constituted ≥ 10% of the total area of the ipsilateral atrium, it was considered an extensive LVA (ELVA). A total of 271 patients (male 58.3%, median age 63 years) were enrolled. Biatrial 3D-EAM found that the RA had a larger volume and volume index, longer total activation time, and higher maximum voltage than the LA (P < 0.001). The presence of LVAs, especially ELVAs, was more common in LA (LVAs: 47 patients (17.3%) vs. 29 patients (10.7%), P = 0.011; ELVAs: 26 patients (9.6%) vs. 7 patients (2.6%), P < 0.001). The multivariate logistic analysis revealed that older age, female gender, persistent AF, and LA enlargement were independent predictors of LA LVAs, while female gender and AF duration were associated with RA LVAs. Strong associations were found between variables reflecting the LA and the RA remodeling. Multivariate Cox regression indicated that ELVA in the LA was the only independent predictor of post-ablation recurrence. AF patients had different characteristics and intrinsic correlations between LA and RA remodeling. The LVAs, especially the ELVAs, were more prevalent in the LA than in the RA. There were distinctions in related factors and impacts on ablation efficacy between the LA LVAs and the RA LVAs.


  • Open Access

    Ameliorating Myocardial Infarction by Concurrent Pyroptosis Suppression and On-Demand Oxygen Production via Functionalized Nanocarrier

    by Wenwu Zhu, Yao Lu, Bin Zong, Ziyi Chen, Yong Ma, Haoran Wang, Peng Cao, Bing Han

    The ideal treatment for myocardial infarction should address the critical issues of oxygen supply improvement in the infarcted area and prevention of myocardial cell death. Myocardial necrosis is a reversible process, but the challenge lies in mitigating the irreversible pyroptosis of cardiomyocytes, which significantly impedes the recovery of cardiac function. To tackle these complexities, here we have developed MnO2@INN@Alb (MIA) nanoparticles. MIA nanoparticles possess the unique ability to generate oxygen and release glibenclamide (INN) in response to the acidic and H2O2-rich environments present in the infarcted region. MIA plays a dual role by inhibiting the pyroptosis process of cardiomyocytes through the suppression of NLRP3 and by providing vital oxygen to alleviate hypoxia. The results shows that MIA can effectively reverse cardiomyocyte hypoxia, reduce infarct fibrosis, and aid in the reconstruction of myocardial vessels. Moreover, MIA demonstrates high biocompatibility, making it a promising avenue for the future of myocardial infarction improvement. We anticipate that MIA can pave the way for novel solutions and research paradigms in the field.


  • Open Access

    Identification of left atrial wall thickness in substrate mapping of atrial fibrillation

    by Wei Liu, Shijie Li, Lina Dou, Chunai Hu, Bing Han

    Objective: The objective of this study was to assess the clinical relevance of left atrial wall thickness (LAWT) in identifying electrophysiological substrate abnormalities.Methods: Eighty-two patients with atrial fibrillation undergoing first-time catheter ablation at Xuzhou Central Hospital between March 2016 and May 2023 were enrolled in this study. The left atrium was anatomically segmented into five regions, with all patients undergoing delayed gadolinium-enhanced magnetic resonance imaging (LGE-MRI) for quantitative assessment of parameters including left atrial wall thickness (LAWT, epicardial fat excluded). Bipolar voltage mapping was systematically performed to delineate low-voltage zones (LVZs) and calculate their relative area proportion within the total atrial surface for each patient. The regional segmentation method for left atrial voltage mapping was consistent with that used in late gadolinium-enhanced magnetic resonance imaging (LGE-MRI). Univariate and multivariate logistic regression analyses were conducted to identify clinical factors associated with LVZ formation. Receiver operating characteristic (ROC) curve analysis was employed to determine the optimal LAWT cutoff value for LVZ prediction, along with its corresponding sensitivity and specificity. Additionally, regional comparative analyses were performed between LGE-MRI-derived wall thickness measurements and their corresponding low-voltage zones identified by three-dimensional electroanatomic mapping.Results: The study cohort comprised 82 atrial fibrillation patients (44 paroxysmal AF, 38 persistent AF). Mean LAWT significantly differed between paroxysmal and persistent AF groups (2.6 ± 0.5 mm vs. 2.3 ± 0.4 mm, P = 0.02). Multivariate analysis identified age (OR = 1.111, 95% CI:1.03–1.19, P = 0.007), left atrial volume (OR = 1.029, 95% CI:1.003–1.055, P = 0.026), and LAWT (OR = 0.044, 95% CI:0.007–0.272, P = 0.001) as independent predictors of LVZs. Regional analysis revealed the septal wall was thinnest (1.76 ± 0.9 mm), followed by posterior (1.95 ± 0.4 mm) and bottom walls (2.62 ± 0.6 mm), with roof (2.89 ± 0.5 mm) and anterior walls (3.0 ± 0.4 mm) being thickest. Correspondingly, septal LVZ area was most extensive (22.5 ± 10.2%), exceeding posterior (15.3 ± 10.6%), bottom (12.6 ± 12.0%), roof (11.8 ± 10.0%), and anterior walls (10.8 ± 12.1%). ROC analysis demonstrated LAWT ≤ 2.3 mm predicted LVZs with 71% sensitivity and 68.2% specificity (AUC = 0.723, P < 0.001). Additional predictors included age >64.5 years (AUC = 0.722, sensitivity 65.9%, specificity 73.7%) and left atrial volume >119.2 ml (AUC = 0.682, sensitivity 61.4%, specificity 78.9%).Conclusions: This study demonstrate that LAWT significantly correlate with both atrial fibrillation progression and electroanatomical remodeling. Notably, regions exhibiting LAWT ≤ 2.3 mm predict more extensive LVZs. Our findings suggest that non-invasive LGE-MRI-based measurement of LAWT may enhance the detection rate of left atrial pathological substrates.


  • Open Access

    Different impact of female gender on the outcome of catheter ablation between paroxysmal and persistent atrial fibrillation

    by Wei Du, Wenwu Zhu, Hao Yang, Qingshan Dong, YaLan Fei, Xianjin Li, Shijie Li, Bing Han

    The impacts of gender on the outcome of atrial fibrillation (AF) ablation have been studied previously with contradictory results. Given the heterogeneities in clinical and pathophysiological characteristics between paroxysmal and persistent AF, gender impacts on post-ablation recurrence might differ depending on the type of AF. This study aimed to investigate the differing impacts of female gender on catheter ablation outcomes between paroxysmal and persistent AF. A total of 857 patients (537 (62.7%) males and 320 (37.3%) females) undergoing de novo catheter ablation of AF were included in this retrospective study. Gender differences in ablation outcomes for different types of AF were compared. Of all patients, 476 were diagnosed with paroxysmal AF (PAF) and 381 with persistent AF (PeAF). Compared to male patients, female patients were older (64.0 ± 8.9 vs. 59.5 ± 10.7 years, P < 0.001), and more likely to have PAF (64.4% vs. 50.3%, P < 0.001). During a median follow-up of 53 [37–72] months, the total atrial tachyarrhythmia (ATa) recurrence rate after a single procedure was 35.4%, with no difference between male and female patients (34.5% vs. 36.9%, P = 0.473). For PAF, the recurrence was slightly higher in males than in females (37.4% vs. 30.1%, P = 0.096). On the contrary, for PeAF, females had a significantly higher risk of recurrence than males (49.1% vs. 31.5%, P = 0.001). The multivariate Cox regression analysis showed that female gender was an independent predictor of post-ablation recurrence only in PeAF (HR = 1.686; 95% CI 1.196–2.377, P = 0.003). The female gender had different impacts on the outcome of catheter ablation between PAF and PeAF. The ATa recurrence was significantly higher in females than males only for PeAF. Not applicable.


  • Open Access

    Superwide Left Atrial Circumferential Ablation for Persistent Atrial Fibrillation: A Randomized Controlled Trial

    by Yue Cao, Wei Du, Yalan Fei, Hao Yang, Meng Wang, Qingshan Dong, Xianjin Li, Shijie Li, Bing Han

    Background: It remains to be answered whether further enlargement of the isolation area in the left atrium (LA) could produce better effectiveness than pulmonary vein antrum isolation (PVAI) for treatment of atrial fibrillation (AF).Aims: To assess the effectiveness of superwide left atrial circumferential ablation (SWLACA) for treatment of persistent AF (PeAF) through a randomized controlled study.Methods: A total of 248 patients (male 63.7%, median age 65 years) with PeAF were randomly divided into the SWLACA group and PVAI group. The circumferential lines were located 2–3 cm from the PV ostia in the SWLACA group and approximately 1 cm in the PVAI group, respectively. The primary endpoint was the recurrence of atrial tachyarrhythmia after a single procedure.Results: Conduction block between LA and pulmonary veins (PVs) were achieved in all patients. The isolation areas were obviously larger in the SWLACA group (p < 0.001). Compared with the PVAI group, the SWLACA group was associated with a longer procedure duration (p = 0.013) and fluoroscopic time (p = 0.038). During the 12‐month follow‐up, the overall recurrence rate of atrial tachyarrhythmia after a single procedure was not significantly different between the two groups (21.0% vs 26.6%; p = 0.297). However, the SWLACA group had significantly fewer AF recurrences (12.9% vs. 25.0%; p = 0.015), and more atrial tachycardia recurrences (8.1% vs. 1.6%; p = 0.018). After multiple procedures, the SWLACA group had a significantly higher total arrhythmia recurrence‐free rate (p = 0.030).Conclusions: Compared with PVAI, although SWLACA did not significantly decrease the overall arrhythmia recurrence rate for PeAF, it was associated with a notable reduction in the recurrence of AF.